Does Propecia cause gynaecomastia? This is a clinically important question for any man considering or currently taking finasteride 1 mg for male pattern hair loss. Gynaecomastia — the development of enlarged or tender breast tissue in men — is listed as an uncommon but recognised adverse effect in the UK Summary of Product Characteristics (SmPC) for Propecia. Understanding why this occurs, how frequently it is reported, and what steps to take if you notice breast changes is essential for making an informed decision about your treatment. This article explains the hormonal mechanism involved, relevant MHRA guidance, and when to seek medical advice.

Can Propecia Cause Gynaecomastia?

Yes, gynaecomastia is listed as an uncommon adverse effect in the UK SmPC for finasteride 1 mg; any breast swelling, tenderness, lumps, or nipple discharge should be promptly assessed by a doctor to exclude serious causes including male breast cancer.

Propecia is a brand-name medication containing finasteride 1 mg, licensed in the UK for the treatment of male pattern hair loss (androgenetic alopecia). Like all medicines, it carries a risk of side effects, and gynaecomastia — the development of enlarged or tender breast tissue in men — is listed as a recognised, albeit uncommon, adverse effect in the UK Summary of Product Characteristics (SmPC) for finasteride 1 mg.

Gynaecomastia occurs when there is an imbalance between oestrogen and androgen activity in male breast tissue. Because finasteride works by altering the body's hormonal environment, it can, in some men, create conditions that favour breast tissue growth. It is important to note that not all men who take Propecia will experience this side effect, and for the majority, the medication is well tolerated.

If you are taking Propecia and notice any changes to your chest — such as breast swelling, tenderness, lumps, or nipple discharge — do not dismiss these symptoms. The SmPC for finasteride 1 mg includes a specific warning that male breast cancer has been reported in men taking finasteride; patients should be instructed to promptly report any breast changes to their doctor. Whilst gynaecomastia associated with finasteride is generally benign, any new breast change in a man warrants prompt medical assessment to exclude other causes, including rare but serious conditions such as male breast cancer.

Certain features require urgent assessment — ideally via a GP-initiated two-week-wait (2WW) referral to a breast clinic in line with NICE guideline NG12 (Suspected Cancer: Recognition and Referral). These red-flag features include:

• A hard, irregular, or fixed breast lump

• Skin changes over the breast (dimpling, puckering, or redness)

• Nipple changes (inversion, ulceration, or blood-stained discharge)

• Palpable axillary lymph nodes

If you notice any of these features, contact your GP without delay.

How Finasteride Affects Hormone Levels in Men

Finasteride blocks 5-alpha reductase type II, reducing DHT by approximately 60% and modestly raising testosterone, which can be converted to oestradiol via aromatase, shifting the hormonal balance towards oestrogen activity in susceptible men.

To understand why Propecia may cause gynaecomastia, it helps to understand its mechanism of action. Finasteride is a 5-alpha reductase inhibitor. It works by blocking the enzyme 5-alpha reductase type II, which is responsible for converting testosterone into dihydrotestosterone (DHT) — a more potent androgen that drives hair follicle miniaturisation in genetically susceptible men.

By inhibiting this conversion, finasteride reduces DHT levels in the scalp and bloodstream. According to the UK SmPC for finasteride 1 mg, DHT levels are reduced by approximately 60% at the 1 mg dose. This also leads to a modest, relative increase in circulating testosterone in some users. In susceptible individuals, a proportion of this excess testosterone may be converted by the enzyme aromatase into oestradiol (a form of oestrogen). It is this shift in the testosterone-to-oestrogen ratio — with relatively higher oestrogen activity — that is thought to stimulate breast tissue growth in some men.

Key hormonal changes associated with finasteride use include:

• Reduced DHT levels (by approximately 60% at the 1 mg dose, per the SmPC)

• Modestly elevated testosterone in some users

• Potential small increase in oestradiol via peripheral aromatisation — though any such changes are clinically variable and generally modest

These hormonal shifts are typically small at the 1 mg dose used in Propecia, and most men do not experience clinically significant changes. However, individual variation in enzyme activity and hormonal sensitivity means that some men are more susceptible to these effects than others. The BNF finasteride monograph and the SmPC both reflect this pharmacological profile.

How Common Is Gynaecomastia as a Side Effect?

Gynaecomastia is classified as uncommon in the UK SmPC, affecting an estimated 1 in 100 to 1 in 1,000 finasteride users; symptoms often resolve after stopping the drug, though persistence has been reported.

According to the UK SmPC for finasteride 1 mg, gynaecomastia — including breast enlargement and breast tenderness — is classified as an uncommon adverse effect, meaning it is estimated to affect between 1 in 100 and 1 in 1,000 users. This classification is based on data from clinical trials and post-marketing surveillance.

In clinical studies conducted prior to licensing, breast tenderness and enlargement were reported in a small percentage of participants taking finasteride compared with placebo. Post-marketing reports have added further cases, though it remains difficult to establish precise population-level incidence figures, as many cases may go unreported or be attributed to other causes.

It is also important to distinguish between:

• True gynaecomastia — proliferation of glandular breast tissue, which may feel firm or rubbery beneath the nipple

• Pseudogynaecomastia — fatty tissue accumulation without glandular involvement, which is not directly caused by finasteride

In most reported cases, gynaecomastia associated with finasteride improves after discontinuation of the drug, though resolution may take several months. However, persistence after stopping treatment has been reported; the frequency of persistent cases is not precisely known. Where breast changes do not resolve, or where they are significant, referral for specialist assessment — to a breast clinic or endocrinologist, depending on clinical findings — may be warranted. NICE CKS guidance on gynaecomastia provides a useful framework for workup and referral in UK practice.

MHRA Guidance and Reported Cases in the UK

The MHRA requires finasteride's SmPC to warn that male breast cancer has been reported in users; breast changes should be reported to a doctor promptly and can be submitted to the MHRA via the Yellow Card scheme.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for monitoring the safety of medicines, including Propecia. Gynaecomastia has been included in the product labelling for finasteride for a number of years, reflecting both clinical trial data and post-marketing reports submitted through the Yellow Card scheme — the UK's pharmacovigilance reporting system.

The current UK SmPC for finasteride 1 mg includes a specific special warning stating that male breast cancer has been reported in men taking finasteride, and that patients should be instructed to promptly report any breast changes — including breast lumps, pain, gynaecomastia, or nipple discharge — to their doctor. Prescribers are expected to counsel patients about this risk before initiating treatment. The MHRA has previously issued Drug Safety Updates on finasteride relating to sexual side effects and psychiatric adverse reactions; breast changes are addressed within the product's SmPC warnings and adverse reactions sections.

Experiencing these side effects? Our pharmacists can help you navigate them →

Patients and healthcare professionals in the UK are encouraged to report suspected adverse drug reactions — including gynaecomastia — via the Yellow Card scheme (available at yellowcard.mhra.gov.uk). Reporting helps regulators identify emerging safety signals and update guidance accordingly. If you believe you have experienced gynaecomastia as a result of taking Propecia, submitting a Yellow Card report is a straightforward and valuable step, regardless of whether you are certain the drug is responsible.

What to Do If You Notice Breast Changes on Propecia

Contact your GP promptly if you develop breast swelling, tenderness, a firm lump, or nipple discharge while taking Propecia; red-flag features such as a hard fixed lump or blood-stained discharge require urgent assessment and possible 2WW referral under NICE NG12.

If you are taking Propecia and develop any of the following symptoms, contact your GP promptly:

• Swelling or enlargement of one or both breasts

• Tenderness or pain in the breast or nipple area

• A firm lump beneath the nipple

• Nipple discharge of any kind

Whilst gynaecomastia caused by finasteride is typically benign, it is essential that a healthcare professional evaluates any new breast change in a man. Male breast cancer, although rare, can present similarly, and a clinical assessment is needed to differentiate between causes.

If any of the following red-flag features are present, seek urgent GP assessment, as a two-week-wait (2WW) referral to a breast clinic may be required in line with NICE NG12:

• A hard, irregular, or fixed lump

• Skin changes over the breast

• Blood-stained nipple discharge

• Nipple inversion or ulceration

• Palpable axillary lymph nodes

Regarding your medication: many clinicians will advise pausing finasteride until you have been assessed, as there is no harm from stopping and breast changes may improve. Do not feel you must continue taking Propecia whilst awaiting review. Your GP or prescriber will assess the severity of your symptoms, consider alternative diagnoses, and discuss the implications of stopping treatment for your hair loss before advising on next steps.

Not sure if this is normal? Chat with one of our pharmacists →

In the meantime, keep a note of:

• When you first noticed the symptoms

• Whether the changes are in one or both breasts

• Any other new symptoms you have experienced since starting Propecia

This information will help your GP conduct a thorough assessment and make an informed decision about your ongoing management. The NHS Medicines A–Z entry for finasteride also provides patient-facing guidance on side effects and when to seek medical help.

Speaking to Your GP or Prescriber About Your Options

Your GP can examine you, arrange hormone and liver function blood tests, and discuss options including pausing finasteride, watchful waiting, specialist referral, or switching to topical minoxidil, which does not carry the same hormonal mechanism.

If you are concerned about gynaecomastia or any other side effect from Propecia, your GP or prescribing clinician is your first point of contact. They can perform a clinical examination — including assessment of the testes, as testicular tumours can cause gynaecomastia — and arrange relevant investigations where indicated.

First-line investigations your GP may consider include blood tests to assess hormone levels (testosterone, oestradiol, LH, FSH, prolactin, and hCG), thyroid function tests (TFTs), and liver function tests (LFTs), as systemic causes of gynaecomastia need to be excluded. If a testicular tumour is suspected, testicular examination and ultrasound may be arranged. Breast ultrasound may also be requested if the clinical picture warrants it.

In terms of management, options your doctor may discuss include:

• Pausing or discontinuing finasteride — in many cases, breast changes improve over time after stopping the medication, though persistence has been reported

• Watchful waiting — if symptoms are mild and the patient wishes to continue treatment, careful monitoring may be appropriate after thorough assessment

• Referral to a breast clinic — for any suspicious or persistent breast mass, or where red-flag features are present, in line with NICE NG12

• Referral to an endocrinologist — for persistent gynaecomastia without a clear drug-related cause, or where an underlying endocrine or systemic condition is suspected, in line with NICE CKS guidance on gynaecomastia

• Alternative hair loss treatments — such as topical minoxidil, which does not carry the same hormonal mechanism and is not associated with gynaecomastia

NICE CKS guidance on androgenetic alopecia (male pattern hair loss) supports a shared decision-making approach, taking into account patient preferences, the severity of hair loss, and the side effect profile of available options. Your GP can help you weigh the benefits of continued finasteride use against the impact of side effects on your quality of life.

Finally, if you obtained Propecia through an online pharmacy or private prescription service, ensure that the prescribing clinician is made aware of your symptoms. All prescribers have a duty of care to monitor patients for adverse effects, and you are entitled to a review regardless of where your prescription originated.

Frequently Asked Questions